Related Experiment Video
Updated: Aug 9, 2026
Immunophenotyping of Orthotopic Homograft (Syngeneic) of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry
Published on: October 9, 2018
Strategies in Developing Immunotherapy for Pancreatic Cancer: Recognizing and Correcting Multiple Immune "Defects" in
Sireesha Upadhrasta1,2,3,4, Lei Zheng5,6,7,8
1The Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Abstract:
With the advent of cancer immunotherapies, significant advances have been made in the treatment of many tumor types including melanoma, lung cancer, squamous cell carcinoma of the head and neck, renal cell carcinoma, bladder cancer, etc. However, similar success has not been observed with the treatment of pancreatic cancer and all other immunogenic "cold" tumors. This prompts the need for a better understanding of the complexity of the cold tumor microenvironment (TME) of pancreatic cancer and what are truly the "defects" in the TME making the cancer unresponsive to immune checkpoint inhibitors. Here we discuss four major immune defects that can be recognized in pancreatic cancer, including lack of high-quality effector intratumoral T cells, heterogeneous dense stroma as a barrier to effector immune cells infiltrating into the tumor, immunosuppressive tumor microenvironment, and failure of the T cells to accomplish tumor elimination. We also discuss potential strategies for pancreatic cancer treatment that work by correcting these immune defects.
Insights
Pancreatic cancer, a "cold" tumor, is unresponsive to immunotherapies due to four immune defects in its tumor microenvironment (TME). Strategies to correct these defects may improve treatment outcomes.
Area of Science:
- Oncology
- Immunology
Background:
- Cancer immunotherapies have advanced treatment for many cancers like melanoma and lung cancer.
- Pancreatic cancer and other immunogenic "cold" tumors have shown limited response to these therapies.
Purpose of the Study:
- To understand the pancreatic tumor microenvironment (TME) defects causing unresponsiveness to immune checkpoint inhibitors.
- To identify key immune defects in pancreatic cancer.
Main Methods:
- Review and discussion of immune defects in pancreatic cancer.
- Analysis of the tumor microenvironment (TME) in pancreatic cancer.
Main Results:
- Identified four major immune defects in pancreatic cancer: lack of effector T cells, stromal barriers, immunosuppressive TME, and T cell elimination failure.
- Highlighted the complexity of the pancreatic TME.
Conclusions:
- Understanding these immune defects is crucial for developing effective pancreatic cancer treatments.
- Strategies targeting these specific defects may enhance immunotherapy efficacy in pancreatic cancer.
More Related Videos
06:16Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity
Published on: December 8, 2019
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
Related Concept Videos
02:17The Tumor Microenvironment
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...